.jpeg)
2026-07-10 06:43:53
An in-depth analysis of Cabozantinib's multi-kinase inhibition mechanism and its established role in treating renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer globally.
2026-07-10 06:37:28
This article provides a comprehensive overview of infusion-related reactions (IRRs) associated with Amivantamab. It covers preventive premedication, step-up dosing strategies, and protocols for managing adverse events in clinical settings.
2026-06-23 06:15:37
This article reviews clinical response patterns of margetuximab combined with chemotherapy for HER2-positive metastatic breast cancer, based on the Phase 3 SOPHIA trial. It details median time to response, RECIST evaluation cycles, key efficacy data, and factors influencing therapeutic outcomes.
2026-06-16 04:31:29
This article presents the eligible population, mechanism of action and clinical positioning of the avutometinib + defactinib combination regimen, and elaborates its clinical value and prerequisite for use in precision treatment of low-grade serous ovarian cancer.
2026-06-12 02:43:12
This article provides a comprehensive overview of vemurafenib (brand name Zelboraf), a targeted therapy for BRAF V600 mutation-positive melanoma. It covers standard dosage, administration instructions, dose adjustment principles, special population considerations, treatment monitoring requirements, and important safety information for patients and healthcare professionals.
2026-06-08 03:30:02
A comprehensive guide to the safety of Durvalumab (Imfinzi), detailing the identification, grading, and management of immune-related adverse events across multiple organ systems.
2026-06-08 03:18:47
Based on pivotal SPOTLIGHT and GLOW Phase III trials, this article analyzes the efficacy, durability of response, and real-world feedback of Zolbetuximab for advanced gastric cancer.
2026-06-08 03:13:03
A comprehensive guide to Mitotane resistance in ACC, covering its definition, mechanisms, and subsequent strategies including chemotherapy, targeted therapy, and clinical trial participation for patients and caregivers.
2026-06-08 02:54:25
Discover the latest 2026 data on Trametinib (Mekinist) plus Dabrafenib for BRAF V600-mutant tumors. This article covers efficacy, global cost insights, dosing, and side effect management for patients and caregivers worldwide.
2026-06-05 06:44:46
This article explains why mitotane, a drug for adrenocortical carcinoma, must not be stopped abruptly, and outlines a safe tapering protocol under medical supervision, including monitoring and management.
2026-06-05 06:17:52
Pemigatinib delivers breakthrough efficacy for patients with advanced cholangiocarcinoma harboring FGFR2 fusions/rearrangements, showing an objective response rate of 35.5% and a median overall survival of 21.1 months in a key study.
2026-06-05 06:10:25
Erlotinib is an oral EGFR tyrosine kinase inhibitor that works by precisely blocking the growth signaling pathways in non-small cell lung cancer cells harboring specific EGFR gene mutations, thereby inhibiting tumor progression.
